Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: No significant effect in a randomized crossover trial

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Finckh, Axel ^a   Mc Carthy, Geraldine M ^b   Madigan, Anne ^b   Van Linthoudt, Daniel ^c   Weber, Marcel ^d   Neto, David ^a   Rappoport, Georges ^e   Blumhardt, Sandra ^f   Kyburz, Diego ^f   Guerne, Pierre Andre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c Hopital de la Chaux de Fonds   (Switzerland)

^d TRIEMLI HOSPITAL   (Switzerland)

^e Centre thermal Yverdon   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ANTIRHEUMATIC AGENT;

ADULT; ADVERSE OUTCOME; AGED; ARTHRITIS; ARTHROPATHY; ARTICLE; BICYTOPENIA; CALCIUM PYROPHOSPHATE DEPOSITION ARTHROPATHY; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE BASED ON 44 JOINT; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MUSCULOSKELETAL DISEASE ASSESSMENT; PAIN ASSESSMENT; POLYARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; CHONDROCALCINOSIS; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; CHONDROCALCINOSIS; CHRONIC DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 84988864302     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-014-0458-4     Document Type: Article

References (20)

1. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Pascual E: European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011, 70:563-570.
2. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, Leeb BF, Perez-Ruiz F, Pimentao J, Punzi L, Richette P, Sivera F, Uhlig T, Watt I, Bardin T: EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011, 70:571-575.
3. Announ N, Palmer G, Guerne PA, Gabay C: Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009, 76:424-426.
4. Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G: Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol 2012, 18:310-311.
5. Chan ES, Cronstein BN: Methotrexate-how does it really work? Nat Rev Rheumatol 2010, 6:175-178.
6. Chollet-Janin A, Finckh A, Dudler J, Guerne PA: Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum 2007, 56:688-692.
7. Andres M, Sivera F, Pascual E: Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol 2012, 18:234-236.
8. Doan TH, Chevalier X, Leparc JM, Richette P, Bardin T, Forestier R, French Society for Rheumatology Osteoarthritis S: Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum 2008, 58:2210-2211.
9. Kohn NN, Hughes RE, Mc CD Jr, Faires JS: The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the "pseudogout syndrome". II. Identification of crystals. Ann Intern Med 1962, 56:738-745.
10. Efficacy of methotrexate on chronic calcium pyrophosphate dihydrate deposition disease (chondrocalcinosis). [http://www.controlled-trials.com/ ISRCTN79343755]
11. Braun J, Kastner P, Flaxenberg P, Wahrisch J, Hanke P, Demary W, von Hinuber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A, Group M-MRS: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008, 58:73-81.
12. Fransen J, van Riel PL: The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005, Suppl 39:S93-S99.
13. Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H, Group OSI: Outcome measures for acute and chronic gout. J Rheumatol 2005, 32:2452-2455.
14. Société Suisse de Rhumatologie/Schweizer Geselschaft für Rheumatologie: Recommendations pour les traitements de base de Methotrexate. 2004.
15. van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001, 44:1515-1524.
16. Jones B, Kenward MG: Design and Analysis of Cross-Over Trials. In: Monographs on Statistics and Applied Probability. Chapman and Hall; 1989.
17. R Development Core Team: R: A language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria; 2008.
18. Kawabe Y, Eguchi K, Tsuboi M, Kita M, Tsukada T, Takashima H, Mizokami A, Kawakami A, Matsuoka N, Migita K, Nagataki S: Untoward effects of low dose methotrexate therapy in rheumatoid arthritis. Ryumachi [Rheumatism] 1996, 36:514-521.
19. Duxbury B, Combescure C, Chizzolini C: Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 2013, 22:1489-1503.
20. Zhang Y, Brown MA: Genetic studies of chondrocalcinosis. Curr Opin Rheumatol 2005, 17:330-335.